SkyWater Technology, Inc. Common Stock
SKYTSkyWater Technology, Inc. is a leading American semiconductor foundry that specializes in advanced manufacturing and process development. The company provides comprehensive fabrication services for integrated circuits, supporting customers in various sectors including aerospace, defense, and consumer electronics. Known for its focus on cutting-edge technology and innovation, SkyWater aims to enable the development of next-generation semiconductor solutions.
Company News
IonQ and Quantinuum are leading the quantum computing race using trapped-ion technology with record-breaking accuracy levels. IonQ achieves 99.99% 2-qubit gate fidelity and is pursuing vertical integration through acquisitions, while Quantinuum offers 99.9975% 1-qubit fidelity and a robust software stack. The analyst favors IonQ due to its accura...
The U.S. government announced over $2 billion in incentives for quantum computing companies under the CHIPS and Science Act, with major investments going to IBM's Anderon startup ($1 billion) and GlobalFoundries ($375 million). However, the article argues the government may have overlooked IonQ, which possesses superior trapped ion technology ach...
IonQ stock surged 15.75% after SkyWater Technology shareholders approved their merger agreement. The acquisition is expected to close in Q2-Q3 2026 and will give IonQ greater control over semiconductor fabrication and packaging capabilities through SkyWater's facilities in Minnesota, Florida, and Texas. Quantum computing peers D-Wave and Rigetti ...
IonQ shares surged 15.25% on Monday following strong Q1 2026 earnings with 755% year-over-year revenue growth to $64.7 million and raised full-year guidance to $260-270 million. The company is advancing its acquisition of SkyWater Technology, expected to close in Q2-Q3 2026, and is supporting a sustainable urban planning initiative. Short interes...
Law firm Brodsky & Smith announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Esperion Therapeutics (ARCHIMED acquisition at $3.16/share), Sila Realty Trust (Blue Owl Capital acquisi...
